01—Abstract
Summary
Summary of the 10-Q filed May 5, 2026. Cited figures are marked; the original filing is the authoritative source.
DuPont de Nemours, Inc. reported first-quarter 2026 net sales of $1,681 milliona, up from $1,612 million in the first quarter of 2025, with organic sales up 2 percent and a 2 percent favorable currency impact.
Income from continuing operations, net of tax, was $150 millionb versus $80 million a year earlier. Net income attributable to DuPont common stockholders was $161 million, compared with a loss of $589 million in the prior-year period, which was driven by discontinued operations. Diluted earnings per share were $0.39, versus a loss of $1.40.
Operating EBITDA rose in both segments: Healthcare & Water Technologies to $244 millionc from $223 million, and Diversified Industrials to $200 million from $185 million. The quarter reflects the completion of the Aramids Divestiture to Arclin on April 1, 2026, for pre-tax cash proceeds of approximately $1.2 billion, a $300 million note receivable, and a common equity interest valued at $325 million. The Aramids Business is presented as discontinued operations, and the filing notes a $16 million additional loss from classification to held for sale in the quarter.
Cash and cash equivalents were $710 milliond at March 31, 2026, and total debt was $3,172 million. Cash provided by operating activities from continuing operations was $232 million, compared with $77 million a year earlier. The filing also details ongoing PFAS-related exposure.
The New Jersey Settlement, with an aggregate cash payment of $875 million payable over 25 years, awaits further hearing on June 24, 2026. The company reports approximately 11,900 personal injury cases in the AFFF MDL and accrued total environmental-related liabilities of $246 million. The company expects to launch a $275 million accelerated share repurchase under its $2 billion authorization, and it plans a 2026 reverse stock split at a ratio between 1-for-2 and 1-for-4, subject to stockholder approval.
02—Key points
Key Highlights
- Net sales of $1,681 million, up from $1,612 million, with organic sales up 2 percent and currency up 2 percent.
- Income from continuing operations, net of tax, of $150 million, compared with $80 million in the first quarter of 2025.
- Net income available for DuPont common stockholders of $161 million, versus a loss of $589 million, with the swing largely reflecting the prior-year $768 million Aramids goodwill impairment in discontinued operations.
- Completed the Aramids Divestiture on April 1, 2026, for approximately $1.2 billion in pre-tax cash proceeds, a $300 million note receivable and a $325 million equity interest.
- Segment Operating EBITDA of $244 million for Healthcare & Water Technologies and $200 million for Diversified Industrials, both up from the prior-year quarter.
- Cash and cash equivalents of $710 million and total debt of $3,172 million at March 31, 2026; cash from continuing operating activities of $232 million.
- PFAS exposure remains significant: the New Jersey Settlement totals $875 million over 25 years, the company's share of the $311 million aggregate payment was valued at $186 million, and approximately 11,900 personal injury cases are pending in the AFFF MDL.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed May 5, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Revenue | $1.68B$1.61B | +4.3% |
| Cost of Revenue | $1.08B$1.07B | +0.9% |
| Gross Profit | $602.00M$543.00M | +10.9% |
| R&D Expenses | $47.00M$50.00M | −6.0% |
| SG&A Expenses | $255.00M$234.00M | +9.0% |
| Net Income | $161.00M-$589.00M | +127.3% |
| EPS (Basic) | $0.39$-1.41 | +127.7% |
| EPS (Diluted) | $0.39$-1.40 | +127.9% |
| Shares Outstanding (Basic) | 410.10M418.50M | −2.0% |
| Shares Outstanding (Diluted) | 412.80M419.90M | −1.7% |
05—Questions
Frequently Asked Questions
How did DuPont perform in the first quarter of 2026?
Net sales rose 4 percent to $1,681 million, driven by 2 percent organic growth and 2 percent favorable currency. Income from continuing operations was $150 million, and diluted earnings per share were $0.39, compared with a loss of $1.40 in the prior-year quarter.
What was the effect of the Aramids Divestiture on the financial statements?
The Aramids Business is reported as discontinued operations, with income of $34 million in the quarter after tax. The divestiture closed April 1, 2026, after the balance sheet date, and the filing records $1,853 million of assets and $299 million of liabilities of discontinued operations at March 31, 2026.
What are the main PFAS-related risks disclosed in the filing?
The New Jersey Settlement requires an aggregate payment of $875 million over 25 years and remains subject to a further court hearing on June 24, 2026. Approximately 11,900 personal injury cases are pending in the AFFF MDL, and the company says it is reasonably possible that costs could exceed the $246 million of accrued environmental obligations.
What capital return actions are planned?
DuPont expects to launch an accelerated share repurchase of $275 million under its $2 billion authorization and paid a $0.20 per share dividend in the first quarter, with a second-quarter dividend of $0.20 payable May 29, 2026. It also plans to seek stockholder approval for a reverse stock split at a ratio of 1-for-2 to 1-for-4.
06—Continue